International Precision Medicine Consortium for Neurooncology Research

Overview

About this study

The purpose of this study is to collect minimal risk normal samples, both prospectively collected and those stored at the patient's home institution and any outside institutions, along with clinical data. For this same end, the study provides for a wide scope of research, including detailed genetic analysis, and provides mechanisms for reporting of results back to participants and/or their treating physicians.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  1. Participant must be suspected of having or is known to have a tumor within/of the nervous system or other disease of the nervous system
  2. Participant, or participant’s authorized legal representative, must consent to the following:
    1. Banking of previously obtained and collection of future unused tissue, blood, and skin during surgery
    2. Providing minimal risk samples just for research purposes, such as blood, buccal swab, and urine during or outside of routine medical procedure
    3. Collection of clinical information, including PHI, from medical records, scans (radiographic neuroimages), and laboratory results
    4. Linkage of clinical information to collected tissues
    5. Providing samples and records from other institutions
    6. Use of samples for the creation of cell lines, genetic testing including whole genome sequencing as well as other available sequencing techniques, research testing (techniques under development), and that samples may be stored indefinitely until used
    7. Use of data and samples to study neurologic diseases and their treatment
    8. Notification of results that may be clinically relevant via their clinician
    9. Derivative products of value may arise for which participants will not have any financial benefit
    10. Participants may withdraw from the study at any time, however data and samples already collected may not be recalled or destroyed
    11. Samples and data to be shared with outside institutions including commercial entities, but samples will never be sold

Exclusion Criteria:

  1. No exclusion criteria are specified

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Evanthia Galanis, M.D.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publications

Publications are currently not available
.
CLS-20438529

Mayo Clinic Footer